India, Sept. 11 -- Biocon Limited, a global innovation-driven biopharmaceutical company, has inaugurated its first U.S. manufacturing facility in Cranbury, New Jersey, through its wholly owned subsidiary, Biocon Generics Inc (BGI). The event was graced by the Honourable Governor of New Jersey, Phil Murphy, along with Biocon Chairperson Kiran Mazumdar-Shaw, senior officials, customers, partners and industry leaders.
The company acquired the Oral Solid Dosage (OSD) facility from Eywa Pharma Inc. in 2023 and has since invested over USD 30 million to transform it into a state-of-the-art manufacturing site with an annual capacity of 2 billion tablets. Several products have already been launched from the facility, with more in the pipeline. This...